The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies

BRAF-targeted therapies are widely used for the treatment of melanoma patients with BRAF V600 mutations. Vemurafenib, dabrafenib as well as encorafenib have demonstrated substantial therapeutic activity; however, as is the case with other chemotherapeutic agents, the frequent development of resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Elshazly, Ahmed M., Gewirtz, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572960/
https://www.ncbi.nlm.nih.gov/pubmed/37834222
http://dx.doi.org/10.3390/ijms241914774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572960/
https://www.ncbi.nlm.nih.gov/pubmed/37834222
http://dx.doi.org/10.3390/ijms241914774

Ejemplares similares